Kiniksa Pharmaceuticals (NASDAQ:KNSA) announced its quarterly earnings results on Thursday. The company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.02), MarketWatch Earnings reports.
KNSA stock opened at $19.52 on Friday. Kiniksa Pharmaceuticals has a 12 month low of $5.01 and a 12 month high of $28.67. The company’s 50-day moving average price is $22.78 and its two-hundred day moving average price is $19.04.
KNSA has been the subject of a number of recent analyst reports. Zacks Investment Research cut shares of Kiniksa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 1st. Wedbush increased their price target on shares of Kiniksa Pharmaceuticals from $30.00 to $38.00 in a research note on Monday, June 29th. BidaskClub cut shares of Kiniksa Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday. ValuEngine cut shares of Kiniksa Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, July 2nd. Finally, BofA Securities raised their target price on shares of Kiniksa Pharmaceuticals from $25.00 to $40.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $31.14.
Kiniksa Pharmaceuticals Company Profile
Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis.
Further Reading: How much can an individual set aside as a catch-up contribution?
Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.